Rifaximin



Indications and Reactions:

Role Indications Reactions
Primary
Hepatic Encephalopathy 50.0%
Diarrhoea 25.0%
Liver Cirrhosis 25.0%
Eosinophilia 16.7%
Irritable Bowel Syndrome 16.7%
Laryngeal Oedema 16.7%
Medication Error 16.7%
Oral Candidiasis 16.7%
Renal Failure Acute 16.7%
Secondary
Product Used For Unknown Indication 25.4%
Self Injurious Behaviour 16.9%
Haemolytic Uraemic Syndrome 8.5%
Drug Use For Unknown Indication 7.0%
Ill-defined Disorder 7.0%
Diabetes Mellitus 4.2%
Diarrhoea 4.2%
Dysentery 4.2%
Crohn's Disease 2.8%
Hepatic Encephalopathy 2.8%
Hypertension 2.8%
Pain 2.8%
Clostridium Difficile Colitis 1.4%
Convulsion 1.4%
Gastric Disorder 1.4%
Hypothyroidism 1.4%
Infection Prophylaxis 1.4%
Localised Infection 1.4%
Phytotherapy 1.4%
Proteinuria 1.4%
Pancreatitis 16.0%
Self Injurious Behaviour 12.0%
Colitis Ischaemic 8.0%
Dysentery 8.0%
Face Oedema 8.0%
Drug Hypersensitivity 4.0%
Laryngeal Oedema 4.0%
Maternal Drugs Affecting Foetus 4.0%
Miosis 4.0%
Multiple Drug Overdose 4.0%
Muscle Spasms 4.0%
Nocturia 4.0%
Pain 4.0%
Rectal Haemorrhage 4.0%
Sepsis 4.0%
Weight Decreased 4.0%
White Blood Cell Count Decreased 4.0%
Concomitant
Product Used For Unknown Indication 27.7%
Crohn's Disease 24.5%
Drug Use For Unknown Indication 10.2%
Inflammatory Bowel Disease 3.9%
Prophylaxis 3.4%
Hepatic Neoplasm Malignant 3.3%
Pain 3.3%
Surgery 2.6%
Hypertension 2.5%
Hepatitis C 2.3%
Anaemia 2.3%
Diarrhoea 2.1%
Hepatic Encephalopathy 1.9%
Gastrooesophageal Reflux Disease 1.7%
Medical Diet 1.7%
Oedema 1.7%
Vitamin Supplementation 1.7%
Nausea 1.2%
Anxiety 1.1%
Hiv Infection 1.0%
Transfusion Reaction 11.8%
Weight Decreased 8.7%
Crohn's Disease 6.3%
Sepsis 6.3%
Hepatic Encephalopathy 5.5%
Electrocardiogram Qt Prolonged 4.7%
Multi-organ Failure 4.7%
Pharyngitis Streptococcal 4.7%
Renal Failure Acute 4.7%
Somnolence 4.7%
Urinary Tract Infection 4.7%
Vomiting 4.7%
Influenza 3.9%
Mental Status Changes 3.9%
Nausea 3.9%
Thrombocytopenia 3.9%
Acute Monocytic Leukaemia 3.1%
Clostridial Infection 3.1%
Colitis Ulcerative 3.1%
Congestive Cardiomyopathy 3.1%